Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | €704.22B | 90.6x | 8.35 | €781.10 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | €704.22B | 90.6x | 8.35 | €777 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly | Vienna | Healthcare | Pharmaceuticals | €703.19B | 90.6x | 8.35 | €767.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk B | BATS Europe | Healthcare | Pharmaceuticals | €453.03B | 37.8x | 1.11 | €102.12 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Frankfurt | Healthcare | Pharmaceuticals | €453.02B | 37.8x | 1.11 | €102.20 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Xetra | Healthcare | Pharmaceuticals | €453.02B | 37.8x | 1.11 | €102.16 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | Vienna | Healthcare | Pharmaceuticals | €453.02B | 37.8x | 1.11 | €102.28 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Frankfurt | Healthcare | Pharmaceuticals | €356.08B | 26.4x | -0.48 | €147.88 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson&Johnson | Xetra | Healthcare | Pharmaceuticals | €356.08B | 26.4x | -0.48 | €148.02 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Vienna | Healthcare | Pharmaceuticals | €355.70B | 26.4x | -0.48 | €147.92 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Frankfurt | Healthcare | Pharmaceuticals | €332.04B | 71.4x | -1.63 | €186.40 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Vienna | Healthcare | Pharmaceuticals | €332.04B | 71.4x | -1.63 | €183 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding DRC | Frankfurt | Healthcare | Pharmaceuticals | €249.04B | 22x | -6.57 | €36 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | €248.48B | 22x | -6.57 | €284.85 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | €248.48B | 22x | -6.57 | €311.85 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | €237.91B | 18.7x | -1.09 | €93.80 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co | Vienna | Healthcare | Pharmaceuticals | €237.91B | 18.7x | 0.06 | €95.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Frankfurt | Healthcare | Pharmaceuticals | €237.34B | 18.7x | 0.06 | €93.40 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €237.01B | 18.7x | 0.06 | €93.20 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca | BATS Europe | Healthcare | Pharmaceuticals | €204.85B | 34.3x | 8.48 | €132.18 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | €203.30B | 34.3x | 8.48 | €66.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | €203.21B | 34.3x | 8.48 | €131.60 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | €203.21B | 34.3x | 8.48 | €131.60 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Vienna | Healthcare | Pharmaceuticals | €203.10B | 34.3x | 8.48 | €66.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | BATS Europe | Healthcare | Pharmaceuticals | €203.03B | 34.3x | 8.38 | €131.37 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | BATS Europe | Healthcare | Pharmaceuticals | €199.22B | 12.5x | 0.19 | €99.63 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Xetra | Healthcare | Pharmaceuticals | €159.29B | 54.8x | -0.89 | €294.40 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Frankfurt | Healthcare | Pharmaceuticals | €159.29B | 54.8x | -0.89 | €292.40 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Vienna | Healthcare | Pharmaceuticals | €159.11B | 54.8x | -0.89 | €294.75 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Vienna | Healthcare | Pharmaceuticals | €148.83B | 38x | 0.55 | €25.56 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |